Physician profile
Patrick E Prath
NPI 1659799708
$9,989.74
in general payments reported to CMS, 2019-2025
55 companies · $1,755 in 2025
The $1,755 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,337 · 2020: $398 · 2021: $168 · 2022: $1,483 · 2023: $2,749 · 2024: $2,100 · 2025: $1,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,842 · Education: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,841.78 |
| Education | $762.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,002.55 | 2019-2025 | |
| Celgene Corporation | $790.85 | 2019-2025 | Pomalyst, Reblozyl, Opdualag |
| Seagen INC. | $769.88 | 2019-2025 | Padcev, Adcetris, Tukysa |
| Janssen Biotech, INC. | $685.06 | 2021-2025 | Erleada, Talvey, Darzalex |
| Astrazeneca Pharmaceuticals Lp | $619.58 | 2019-2025 | Enhertu, Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $589.90 | 2019-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $416.42 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $395.63 | 2019-2024 | Ultomiris |
| Genzyme Corporation | $365.49 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $345.99 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $302.36 | 2024-2025 | Enhertu, Vanflyta |
| Astellas Pharma US INC | $222.69 | 2023-2025 | Xospata, Vyloy, Padcev |
| Incyte Corporation | $222.55 | 2019-2025 | Jakafi, Monjuvi, Niktimvo |
| Regeneron Healthcare Solutions, INC. | $219.78 | 2022-2023 | Libtayo |
| Tempus Ai, INC | $210.55 | 2024 | Xt Cdx |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $183.02 | 2021-2023 | Xarelto |
| Abbvie INC. | $175.85 | 2021-2025 | |
| Lilly USA, LLC | $158.29 | 2020-2025 | Verzenio, Jaypirca, Retevmo |
| Boston Scientific Corporation | $155.35 | 2022 | |
| Glaxosmithkline, LLC. | $131.69 | 2022-2024 | Shingrix, Ojjaara, Jemperli |
| Aveo Pharmaceuticals, INC. | $129.26 | 2023-2025 | Fotivda |
| Eisai INC. | $127.30 | 2023-2025 | |
| Amgen INC. | $124.07 | 2022-2023 | Kyprolis, Lumakras, Blincyto |
| Adc Therapeutics America, INC. | $118.93 | 2024-2025 | |
| Taiho Oncology, INC. | $93.78 | 2022-2025 | |
| Gilead Sciences, INC. | $93.67 | 2023-2024 | Trodelvy |
| Apellis Pharmaceuticals, INC. | $87.20 | 2024 | Empaveli |
| Sobi, INC | $86.86 | 2022-2024 | |
| Dendreon Pharmaceuticals LLC | $86.23 | 2025 | Provenge |
| Puma Biotechnology, INC. | $82.33 | 2023-2025 | Nerlynx |
| Array Biopharma INC | $74.78 | 2023-2024 | Lorbrena, Braftovi, Mektovi |
| Karyopharm Therapeutics INC. | $72.18 | 2022-2023 | Xpovio |
| Morphosys, US INC. | $71.38 | 2022-2023 | Monjuvi |
| Rigel Pharmaceuticals, INC. | $70.19 | 2019-2024 | Rezlidhia, Tavalisse |
| Bayer Healthcare Pharmaceuticals INC. | $57.27 | 2024-2025 | |
| Foundation Medicine, INC. | $55.74 | 2022 | |
| Tactile Systems Technology INC | $54.90 | 2022-2023 | Entre Plus, Flexitouch Plus |
| Jazz Pharmaceuticals INC. | $51.82 | 2025 | |
| Cti Biopharma Corp. | $51.34 | 2022-2023 | Vonjo |
| Pharmaessentia USA Corporation | $48.94 | 2023-2025 | Besremi |
| Adaptive Biotechnologies Corporation | $47.24 | 2022-2023 | Clonoseq |
| Beigene USA, INC. | $38.55 | 2023-2024 | Brukinsa |
| Sumitomo Pharma America, INC. | $28.93 | 2025 | Orgovyx |
| Pharmacosmos Therapeutics INC. | $28.31 | 2025 | Monoferric |
| Amag Pharmaceuticals, INC. | $27.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.26 | 2023 | Ninlaro |
| Pharmacyclics LLC, An Abbvie Company | $26.10 | 2020 | |
| Tolmar, INC. | $24.88 | 2024 | |
| Myovant Sciences INC. | $22.26 | 2022 | |
| Immunocore Limited | $22.17 | 2023 | Kimmtrak |
| Curium US LLC | $20.38 | 2023 | |
| Stemline Therapeutics INC. | $20.19 | 2024 | Orserdu |
| Caris Mpi, INC. | $19.19 | 2025 | Mi Cancer Seek |
| Genentech USA, INC. | $18.80 | 2023 | Polivy, Lunsumio |
| Teva Pharmaceuticals USA, INC. | $17.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Prath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.